Tamper Evident Pharmaceutical Packaging in the UK
3 September 2026
You've got a UK pharmaceutical line going live tomorrow. A returned batch has a torn seal, one leaflet is missing, and nobody can agree whether the pack was opened in transit, mishandled at dispensing, or deliberately interfered with. The old answer, “It complies with the Falsified Medicines Directive”, no longer gives a Great Britain buyer enough control.
Tamper evident pharmaceutical packaging in the UK now has to be specified against the post-Brexit split between Great Britain and Northern Ireland, the optional status of unique identifiers in Great Britain, and the mandatory ‘UK Only' marking. The pack still needs to show visible interference clearly, survive normal distribution, and support the operational requirements of wholesalers, hospitals, pharmacies and retailers.
| UK market or requirement | What the buyer must account for |
|---|---|
| Great Britain | The EU verification system no longer operates for medicines placed on the UK market. A unique identifier isn't required for PLGB packs, although MHRA encourages firms to retain the tamper-evident device. |
| Northern Ireland | The EU safety-features regime still applies to medicines with PL or PLNI authorisations. Each pack requires a unique identifier and a tamper-evident device. |
| UK market packs | From 1 January 2025, packs must carry a clearly legible ‘UK Only' label in at least 7-point font. |
| Optional traceability | Manufacturers may still add a 2D Data Matrix code and serial number to UK packs, but these features aren't mandatory for the UK market. |
| Procurement priority | Specify the physical evidence, artwork controls, inspection rules and distribution testing, not just a sticker described as “security”. |
That distinction matters because tamper evidence is a physical control, not the same thing as a scan result. Professional guidance notes that a UK pack can generate a false FMD alert when scanned in software configured for EU verification, while the pack may still be supplied if a valid local rule doesn't prevent it. The condition of the seal and the result of a verification system are separate checks. Professional guidance on falsified medicines and verification alerts explains that difference clearly.
Table of Contents
- Why Tamper Evidence Still Matters for UK Pharmaceutical Packs
- The Main Tamper-Evident Formats Available to UK Buyers
- Comparing Seals, Bags, Tapes and Blister Formats Side by Side
- MHRA Rules and the GB Versus NI Compliance Split
- Material Trade-Offs for Pharmaceutical Grade Packs
- Testing Standards and What to Ask Suppliers
- Supplier Selection and Cost Versus Volume
- Matching the Right Format to Your Product
Why Tamper Evidence Still Matters for UK Pharmaceutical Packs
The commercial case remains strong even where Great Britain no longer follows the old EU verification model. The UK pharmaceutical packaging market is estimated at US$9,813.5 million in 2025, with a projection of US$18,921.7 million by 2030 and a 14.0% CAGR over that period, according to UK pharmaceutical packaging market analysis. A market of that scale makes packaging specifications commercially significant. A minor change to a seal, carton closure or bag construction can affect a substantial production programme.
Specify evidence that survives real handling
A cosmetic security sticker can look convincing on a sample bench and fail at a courier hub. Heat, cold, condensation, carton abrasion and vibration can lift an adhesive, blur printed evidence or create false damage. Buyers should reject any format that only proves an opening when the pack is handled carefully.
A proper specification should answer four questions:
- What does the user see? The opening must leave an unmistakable mark, broken closure, exposed message or damaged substrate.
- Where does the evidence appear? Place it where a pharmacist, warehouse operator or patient will notice it without dismantling the pack.
- Can the pack be resealed convincingly? If a motivated person can remove and reapply the feature without visible damage, the design is weak.
- What happens after normal transit? A seal that fails during ordinary distribution creates returns and dispensing disputes rather than useful protection.
Procurement rule: Don't approve a tamper-evident feature from a static sample alone. Approve the complete pack after line trials and realistic distribution testing.
Tamper evidence also supports returns control, diversion prevention and pack-integrity decisions. Wholesalers, hospitals and retailers may continue to require visible anti-tamper features because their receiving and dispensing teams need a quick physical signal. That expectation exists independently of whether a Great Britain pack carries an optional serial number.
The Main Tamper-Evident Formats Available to UK Buyers
Four format families cover most UK pharmaceutical applications. They protect different layers of the pack, so choosing between them isn't a simple price comparison.
Induction and heat seals
An induction seal sits beneath a bottle closure and protects the primary container opening. The user must break or remove it before accessing the liquid, powder or tablets. It's a strong choice for solid oral doses in bottles and for liquids where a visible seal provides an immediate integrity check.
The main failure risk is process-related. Poor cap torque, an unsuitable liner, a contaminated bottle lip or inconsistent induction energy can produce weak seals. The supplier should validate the seal across the actual bottle, closure and product configuration, not a similar-looking laboratory sample. Add a shrink band when the outer closure also needs visible evidence.
Security bags and pouches
A tamper-evident bag provides chain-of-custody evidence around the whole shipment or kit. A permanent VOID seal, destructible adhesive or sequential identification can show an attempted opening during a pharmacy transfer, clinical trial handover or controlled-drug movement.
Bags are useful when the contents vary or when a carton cannot carry all required evidence. Their weakness is poor closure discipline. If staff don't inspect the seal at every handover, the feature loses much of its operational value. Tamper-evident bags for pharmaceutical handling are worth comparing by seal construction, overprint area and closure workflow, not just by bag thickness.
Tamper-evident tapes and labels
Tape and labels protect the secondary carton or transport unit. A destructible label can prevent clean reopening of a carton flap, while a printed tape can make interference visible on an outer case or pallet sleeve. They're flexible and easy to add to an existing process.
They're also the easiest format to misuse. A label applied over dust, cold condensation or an uneven carton surface may lift without tampering. A narrow label placed away from the opening won't provide useful evidence. Review tamper-evident tape options with the actual carton board, adhesive surface and storage conditions.
Blister and child-resistant formats
A blister's foil lid or lidding structure makes access visible at the individual dose level. Push-through blisters are generally suitable for tablets in clinic and hospital packs, while child-resistant formats add a separate access-control requirement. Their principal failure mode is false damage from compression, poor cavity design or rough transport.
The layer matters. A bottle seal doesn't replace a carton closure, and a pallet sleeve doesn't prove that a bottle was unopened. British Standards and MHRA guidance establish important outcomes, but buyers still need to define the construction, placement, inspection and acceptance criteria in the purchase specification.
The following video provides useful visual context for how tamper-evident bag construction works in practice.
Comparing Seals, Bags, Tapes and Blister Formats Side by Side
No single format wins across every pharmaceutical line. An induction seal gives strong primary-container protection, while a bag gives better custody evidence around a variable shipment. Blister packs control access to each dose, whereas tape is often the quickest retrofit for an outer carton.
| Format | Protection Level | Line Speed Fit | Cost per Pack | MHRA Compliance Fit |
|---|---|---|---|---|
| Induction or heat seal | High for bottle-opening evidence | Strong when the bottle and sealer are validated together | Usually efficient at established volume | Fits the expectation for a visible anti-tamper feature where used with the correct pack architecture |
| Security bag or pouch | High for shipment custody and handover control | Good for manual or semi-automated fulfilment, less suitable where every unit runs through a bottle line | Depends heavily on bag construction, print and numbering | Useful operational control, but it doesn't replace required pack markings or NI safety features |
| Tamper-evident tape or label | Moderate to high for carton or case opening | Strong for automated labelling or carton sealing | Often economical for secondary packaging | Supports visible pack integrity when correctly positioned and durable |
| Blister and CR format | High at dose level, with added child-resistant access control where specified | Strong on dedicated blister lines after tooling and validation | Tooling and material choice affect total cost | Suitable where the blister itself provides the required visible evidence, subject to product and market rules |
Protection versus throughput
A contract packer running bottles at line speed should prefer an integrated seal-and-cap process over a manually applied security bag. Manual bags can offer better custody evidence for clinical trial kits, but they introduce operator handling, seal inspection and reconciliation requirements.
Blister packs often carry a higher development burden because forming tools, lidding stock and cavity design must work together. That burden can be justified when the product is dispensed as individual doses and the pack needs to show damage at the dose interface.
The cheapest quote can be the expensive option
A low unit price means little if the feature creates reject spikes, false tamper reports or manual rework. Ask suppliers to price total pack cost, including tooling, artwork changes, line modifications, inspection equipment, damaged-pack disposal and retesting.
Don't describe the requirement as “NHS DSCSA-style audits”. DSCSA is a United States framework, not a UK rule. Instead, specify the actual inspection records, traceability expectations and customer acceptance criteria required by your UK contract or distribution network.
A cheap adhesive label that lifts in chilled handling isn't a low-cost control. It's an unplanned returns mechanism.
MHRA Rules and the GB Versus NI Compliance Split
Start with the destination, not the packaging catalogue. The MHRA states that the EU Falsified Medicines Directive safety-features regime no longer applies in Great Britain, while it continues to apply in Northern Ireland. For PLGB medicines, a unique identifier isn't required, although MHRA encourages firms to retain the tamper-evident device. For medicines with PL or PLNI authorisations in Northern Ireland, both a unique identifier and a tamper-evident device are required on each pack. The MHRA guidance on implementing safety features sets out the territorial distinction.
Treat the ‘UK Only' mark as an artwork control
From 1 January 2025, UK market packs must carry a clearly legible ‘UK Only’ label in at least 7-point font. The MHRA notice allowed the mark to be applied by sticker only until 30 June 2025. After that date, it must be printed directly onto the pack. The MHRA-related packaging update also confirms that a 2D Data Matrix code and serial number may still be added voluntarily to UK packs.
That changes the line brief. Reserve artwork space for the mandatory wording, define print permanence, and set inspection tolerances for placement and legibility. Optional traceability features must not crowd the tamper-evident message or interfere with carton folds, seals and machine-readable areas.
Build the market split into the purchase order
Use separate artwork and bill-of-materials controls for GB-only and NI supply wherever the obligations differ. Don't let a supplier assume that an optional Great Britain code satisfies the Northern Ireland requirement. The physical tamper-evident device, unique identifier and market marking each need their own approval record.
The Human Medicines Regulations also provide the legal context for tamper-evident features. In procurement terms, cite the applicable requirement when challenging a weak supplier sample, then describe the exact performance you expect: visible damage on opening, secure adhesion through distribution, and rejection of packs with missing or unreadable evidence.
Material Trade-Offs for Pharmaceutical Grade Packs
Material selection should follow the dosage form, barrier requirement and validated process. Sustainability is important, but a recycled substrate with incomplete extractables, leachables or DPML data isn't ready for a pharmaceutical pack just because it has a better environmental claim.
| Material | Typical formats | Moisture / oxygen barrier | Regulatory acceptance | Relative cost per pack |
|---|---|---|---|---|
| Virgin PVC | Blister base film | Moderate moisture and oxygen protection, depending on structure | Established option where the specification and product compatibility support it | Generally economical |
| PETG | Blister base film and specialist forming applications | Useful clarity and mechanical performance, with barrier dependent on laminate design | Requires product-specific assessment and validated supply documentation | Moderate |
| PVDC-coated structures | Blister films requiring stronger barrier performance | Improved moisture barrier compared with uncoated structures | Established when supported by the approved packaging specification | Higher than basic film structures |
| Aluminium foil | Cold-form blister and foil lidding | Strong protection from moisture, oxygen and light | Widely used where the product requires robust barrier protection | Higher material and forming cost |
| Mono-material or recycled-content alternatives | Bags, films, labels and selected flexible structures | Varies by resin, coating and construction | Accept only with appropriate pharmaceutical data and change control | Varies by specification and supply scale |
Match barrier to the medicine
Standard APET blister film may be acceptable where the dosage form has modest barrier needs and the stability programme supports it. It isn't a universal replacement for cold-form foil. Moisture-sensitive, oxygen-sensitive or light-sensitive products may need a more protective structure, and the decision belongs in the approved pack specification rather than a sustainability presentation.
Virgin PVC can be cost-effective and familiar to converters, but it may not align with every corporate material policy. PETG and mono-material options can support different recyclability objectives, yet their forming behaviour, sealing window and barrier performance must be demonstrated on the production line.
Challenge unsupported recycled claims
Ask for migration information, extractables and leachables assessment, supplier change-control commitments and DPML documentation where relevant. A novel recycled stream can introduce variability in colour, odour, contaminants or seal performance. Those risks don't disappear because the material is used on the outside of a bag or label.
The right question isn't “Is recycled material available?” It's “Can this specific recycled or mono-material structure meet the approved pharmaceutical, barrier, sealing and distribution requirements?” Guidance on sustainable packaging materials can help frame that discussion, but your product risk assessment and validation package must make the final decision.
Testing Standards and What to Ask Suppliers
Testing should prove that the feature works on your pack, through your process and after distribution. A certificate showing that a supplier owns a standard isn't evidence that your bottle seal, pouch closure or carton label will perform.
Turn standards into supplier questions
Use the standards as prompts for evidence:
- ISO 21976: Ask, “What is the seal integrity test procedure for this exact bottle, liner and closure combination?”
- ASTM F1140: Ask, “How is burst strength measured, and what acceptance limit applies to this pouch construction?”
- ASTM D4169: Ask, “What distribution assurance test represents our actual shipping route, pallet pattern and handling environment?”
- EN 13775: Ask, “How do you validate the tamper evidence, and what visible result counts as a pass or fail?”
For induction and heat seals, request seal-strength verification, visual inspection criteria and a defined sampling plan. For pouches, ask for dye penetration and bubble-leak methods where they're appropriate, followed by drop and vibration testing for bagged shipments. Adhesives and inks also need accelerated ageing evidence when the pack has a long shelf life or faces demanding storage conditions.
Ask for records, not assurances
Require the supplier to show validation protocols, deviation reports, change-control procedures and retest frequency. Ask which checks are completed per batch and which are performed during initial qualification only. Third-party certification can demonstrate that a management system or process has been assessed, but it doesn't automatically validate your finished pack.
For telehealth and dispensing operations, the GPHC inspection for UK telehealth provides useful context on why documented controls and patient-safety processes matter beyond the packaging artwork itself.
Supplier questionnaire wording: “Provide the approved test method, acceptance criteria, sampling frequency, deviation process, retest rule and change-notification period for every tamper-evident feature supplied.”
Supplier Selection and Cost Versus Volume
Treat the RFQ as a qualification exercise, not a search for the lowest line item. A supplier that cannot explain capacity, print control or validation evidence can create risk after the purchase order is placed. Specify the same construction, volumes and delivery assumptions for every bidder.
| Criterion | What to ask | Weight | Red flag |
|---|---|---|---|
| Capacity | What output can you allocate to this programme, and how do you manage peak demand? | High | The answer depends on unconfirmed subcontracting |
| Lead time | What is the time from approved PO and artwork to dock delivery? | High | Lead times slip beyond four weeks without explanation |
| Print capability | Can you control microtext, variable numbering, 2D codes and inspection rejects? | High | Print is outsourced without disclosure |
| Certification | Which ISO 15378, ISO 9001, PS 9000 or BRCGS Packaging Materials controls apply? | High | Certificates are supplied without scope or expiry details |
| Price | What is the price per thousand at your planned order volume, including tooling and origination? | Medium | Quote is based only on virgin material or excludes set-up charges |
Score volume breaks realistically
Unit pricing can change at meaningful volume breaks around 250k, 1m and 5m packs. Treat those thresholds as planning points, not guaranteed market statistics. Ask every supplier to quote the same construction at each relevant volume, with tooling, plates, origination, print inspection and freight shown separately.
Smaller runs can become uneconomic when fixed tooling and print costs are spread across fewer packs. Keep the required tamper-evident feature, then compare a stock format, simpler overprint or validated alternative construction. A lower unit price is useful only if the format still meets the specification and production controls.
Use a disciplined shortlist
Send the same technical RFQ to four suppliers. Score the five criteria above, then audit the top two before commitment. Reject any supplier that cannot evidence migration testing, disclose outsourced print, discuss recycled options or explain a lead time beyond four weeks.
Capacity means equipment and output suited to your format, not a broad claim about factory size. Ask for contingency arrangements, approved manufacturing sites and notification procedures if the line, resin or adhesive changes. Confirm who owns tooling, artwork approval and change control before the first production order. These details often determine whether a quoted saving survives scale-up.
Matching the Right Format to Your Product
The product and handover point should determine the format.
Solid oral doses in bulk bottles should normally use an induction seal beneath the closure, with a shrink band where the outer cap also needs visible evidence. Add a security bag only when the distribution route or wholesaler contract requires custody evidence around the entire shipment.
Tablets in clinic or hospital packs generally suit push-through blister with child-resistant lidding where the product and user group require it. The blister gives dose-level evidence without adding a separate bag to every pack, and the carton can carry the required market marking and supporting information.
Liquids, suspensions and clinical trial kits need stronger control around handling and handover. Use a security bag with a permanent VOID seal and sequential numbering when staff must reconcile custody from dispatch to receipt. For clinical trial medication, align the bag number with the kit record and define who inspects the closure.
Injectables and combination packs should use tamper-evident tape over the carton where the outer pack needs an immediate opening signal, with optional 2D-coded serialisation where your operational or customer specification calls for it. Don't treat the code as a substitute for physical evidence.
Controlled drugs need a dedicated track-and-trace bag and a witness seal. A generic mailing bag or an ordinary carton label is not an adequate substitute for a documented custody process.
Before you sign the PO, take three actions:
- Request samples with your real artwork. Check the ‘UK Only' mark, seal position, code space, overprint and leaflet arrangement on the actual pack.
- Run a line trial. Measure feeding, sealing, print inspection, reject handling and operator checks at production conditions.
- Require a signed compliance statement. Obtain a PS 9000 or ISO 15378 compliance statement before the first production run, with the supplier's scope and applicable site clearly identified.
MSP Packaging supplies tamper-evident security bags, pharmacy bags and medical dispensing bags for applications including medicines, samples, patient property, controlled drugs and clinical trial medication. To discuss a UK-ready bag specification, artwork, material choice and production requirement, visit MSP Packaging.